Himalaya: Listen. Learn. Grow.

4.8K Ratings
Open In App
title

TGen Talks

TGen

1
Followers
0
Plays
TGen Talks

TGen Talks

TGen

1
Followers
0
Plays
OVERVIEWEPISODESYOU MAY ALSO LIKE

Details

About Us

TGen Talks explores the human genome to tackle the latest science and discoveries in cancer, neurological disorders, rare diseases, metabolic disorders and infectious disease. Learn about causes and potential cures in our monthly podcast!

Latest Episodes

Episode 31: Make It Personal

Recent events and social protests have prompted increased dialog, and rightly so, on the topic of diversity, equity, and inclusion in America. It's a big topic that covers multiple segments of society. But this edition of TGen Talks will focus on how diversity relates to the fields of science and medicine. Our guest this month on TGen Talks is Dr. Joseph Mikhael,professor of Applied Cancer Research and drug discovery at TGen and Chief Medical Officer of the International Myeloma Foundation, or IMF, and a counselor on the Executive Committee of the American Society of Hematology, who shares his insights on theinto how we all can become better at embracing and understanding differences that make us unique and the value inherent in assessing our own thoughts and beliefs. To Dr. Mikhael, it's not just business, it's personal.

26 min3 d ago
Comments
Episode 31: Make It Personal

Episode 30: Are We There Yet?

275 days ago, the Wuhan Municipal Health Commission in China reported a cluster of cases of pneumonia … a novel coronavirus was eventually identified and labeled COVID-19. Since that time, over 200,000 Americans have died and over 7.1 million have tested positive for the disease. Globally, the number of deaths has reached 1 million with more than 33 million citizens testing positive. Our guest this month on TGen Talks is Dr. David Engelthaler, co-director of TGen North, the Pathogen and Microbiome Division of TGen located in Flagstaff, Arizona, who shares his insights on the latest information and developments surrounding COVID-19 — locally and globally — from testing to the value of masks, and vaccine development.

15 minSEP 24
Comments
Episode 30: Are We There Yet?

Episode 29: Expressions of Interest

Immune cells, also known as white blood cells, help the body fight infection and disease. Now, scientists and clinicians at TGen and City of Hope are using immune cells in combination with chemotherapy drugs to tailor personalized treatments for cancer patients. Specifically, they're using a mathematical formula to predict who might respond best to this type of therapy. This month on TGen Talks, Sunil Sharma, M.D, TGen Deputy Director of Clinical Sciences and Director of the Applied Cancer Research and Drug Discovery Division discusses immunotherapy, this latest advance, and how it could lead to the development of innovative clinical trials in the future.

29 minJUL 29
Comments
Episode 29: Expressions of Interest

Episode 28: A Fresh look at COVID-19

Following the lifting of social restrictions and individuals returning to work, the medical profession has seen a recent spike in COVID-19 cases. This month on TGen Talks, Tyler Delaughder, D.O., a TGen clinical research coordinator and recent graduate of Midwestern University, shares his interpretations of the medical issues surrounding COVID-19. Dr. Delaughder provides insight on the progress of testing and what we might expect next by looking into the past, identifying human error, understanding the power of Mother Nature, and the body’s own genomic complexities.Is there a way of stopping future viruses from developing or are they inevitable? And how is the progress being made in the labs at TGen and TGen North informing the medical profession during this pandemic. All this and more on TGen Talks.

15 minJUN 26
Comments
Episode 28: A Fresh look at COVID-19

Episode 27: Lessons Learned, COVID-19

For nearly 6 months, COVID-19 has raised numerous questions and concerns, as well as having led to global disruption. In addition to testing, TGen was an early adopter in tracking the virus to learn how it mutates and spreads. Joining TGen Talks to discuss what we've learned is Dr. David Engelthaler, co-director of TGen North, the Pathogen and Microbiome Division of TGen located in Flagstaff, Arizona. Dr. Engelthaler discusses what the epidemiology is telling us about COVID-19, and how that plays into decisions states are making on whether to open, and if so, how broadly? He also discusses the global effort toward vaccine development, the possibility of a second wave of COVID-19 in the fall, lessons learned in terms of public health and how we prepare for other viruses in the future.

16 minMAY 27
Comments
Episode 27: Lessons Learned, COVID-19

Episode 26: COVID-19 Immunity

What can a few drops of blood tell scientists about how one’s immune system reacted to COVID-19? If you’re TGen North’s Dr. John Altin, you hope a lot. In this episode of TGen Talks, Dr. Altin discusses a new study entitled the COVID Immunity Study whereby citizen-scientists diagnosed with, and subsequently recovered from, COVID-19 can contribute a few blood spots that will enable Dr. Altin to investigate the antibody response against the SARS-CoV-2 virus, which causes the COVID 19 disease. Through his study Dr. Altin, an Assistant Professor in TGen’s Pathogen and Microbiome Division, hopes to find antibody signatures of exposure that are clear and robust and perhaps even signature that differentiate the different types of disease that people experience. The Holy Grail would be signatures that indicate what type of immune response provides protection, versus one that may do more harm than good. The answer may lie in their immune response. This study may find the answers.

11 minAPR 25
Comments
Episode 26: COVID-19 Immunity

Episode 25: Investigating COVID-19

The COVID-19 coronavirus continues to affect lives on a daily basis. Businesses, churches, schools, and other public facilities are closing. Sporting events and meetings are canceled daily. News reports tell us how hospitals are grappling with limited testing capabilities. There seem to be more questions than answers, and if ever there was a time for answers, it is now. Joining TGen Talks to discuss COVID-19, is Dr. David Engelthaler, co-director of TGen North, the Pathogen and Microbiome Division of TGen located in Flagstaff, Arizona, who discusses the launch of a genomic-based test for COVID-19, and TGen’s collaborative work with the Arizona Department of Health Services to test for and identify pockets of COVID-19 across the state.

14 minMAR 17
Comments
Episode 25: Investigating COVID-19

Episode 24: Reading the Story of Tumors

Our DNA tells the story of who we are genetically. But when we develop cancer, our tumor DNA tells a different version of that story. At Ashion Analytics, a subsidiary of TGen, a patient's tumor sample undergoes testing in a CLIA-certified laboratory —through its flagship test, GEM ExTra— to understand how the story changed and how Ashion can help treating physicians identify actionable steps to help their patients. In episode 24 of TGen Talks, Dr. Janine LoBello, Medical Director and Pathologist of Ashion Analytics, discusses Ashion's beginnings, how their services benefit medical professionals, and a few interesting facts you may not know about the BReast CAncer, or BRCA, gene. Listen now or learn more at ashion.com.

14 minFEB 19
Comments
Episode 24: Reading the Story of Tumors

Episode 23: Tracking Glioblastoma Cell by Cell

The human body contains trillions of individual cells, and inside each resides a unique genetic code. Single-cell RNA sequencing enables researchers to study the mechanics of individual cells and identify the processes underlying disease states — valuable information that helps predict disease susceptibility, or resistance, to drug therapies. This is particularly important in the study of cancer, as cells are constantly mutating. Single-cell sequencing allows investigators to observe these patterns of mutations at a micro-level. In episode 23 ofTGen Talks, Dr. Sen Peng, a computational scientist with TGen’s Brain Tumor Unit, discusses how data from single-cell sequencing allows Dr. Peng and his colleagues to study — and make inroads against — the deadly brain cancer, glioblastoma. Dr. Peng also discusses work with colleagues at City of Hope and elsewhere, and his future plans for studying glioblastoma.

7 minJAN 29
Comments
Episode 23: Tracking Glioblastoma Cell by Cell

Episode 22: Clinical Trials, Drug Development & The Future of Precision Medicine

Over the past decade, cancer treatment has gone from a one-size-fits-all approach to a targeted and personal approach known widely as Precision Medicine. Among the leaders at TGen pushing the boundaries of this new frontier is Dr. Sunil Sharma, Deputy Director of TGen Clinical Sciences, Professor, and Division Director in the Applied Cancer Research and Drug Discovery division. Dr. Sharma is a well-known cancer investigator, responsible for helping develop some of the world’s most advanced anti-cancer agents. In episode 22 ofTGen Talks, Dr. Sharma discusses his work in drug development and patient clinical trials in concert with City of Hope in California, and TGen’s clinical partnership with the HonorHealth Research Institute.Whether in the clinic, or at the bench, his work helps bring precision medicine solutions to patients in need.

16 min2019 DEC 20
Comments
Episode 22: Clinical Trials, Drug Development & The Future of Precision Medicine

Latest Episodes

Episode 31: Make It Personal

Recent events and social protests have prompted increased dialog, and rightly so, on the topic of diversity, equity, and inclusion in America. It's a big topic that covers multiple segments of society. But this edition of TGen Talks will focus on how diversity relates to the fields of science and medicine. Our guest this month on TGen Talks is Dr. Joseph Mikhael,professor of Applied Cancer Research and drug discovery at TGen and Chief Medical Officer of the International Myeloma Foundation, or IMF, and a counselor on the Executive Committee of the American Society of Hematology, who shares his insights on theinto how we all can become better at embracing and understanding differences that make us unique and the value inherent in assessing our own thoughts and beliefs. To Dr. Mikhael, it's not just business, it's personal.

26 min3 d ago
Comments
Episode 31: Make It Personal

Episode 30: Are We There Yet?

275 days ago, the Wuhan Municipal Health Commission in China reported a cluster of cases of pneumonia … a novel coronavirus was eventually identified and labeled COVID-19. Since that time, over 200,000 Americans have died and over 7.1 million have tested positive for the disease. Globally, the number of deaths has reached 1 million with more than 33 million citizens testing positive. Our guest this month on TGen Talks is Dr. David Engelthaler, co-director of TGen North, the Pathogen and Microbiome Division of TGen located in Flagstaff, Arizona, who shares his insights on the latest information and developments surrounding COVID-19 — locally and globally — from testing to the value of masks, and vaccine development.

15 minSEP 24
Comments
Episode 30: Are We There Yet?

Episode 29: Expressions of Interest

Immune cells, also known as white blood cells, help the body fight infection and disease. Now, scientists and clinicians at TGen and City of Hope are using immune cells in combination with chemotherapy drugs to tailor personalized treatments for cancer patients. Specifically, they're using a mathematical formula to predict who might respond best to this type of therapy. This month on TGen Talks, Sunil Sharma, M.D, TGen Deputy Director of Clinical Sciences and Director of the Applied Cancer Research and Drug Discovery Division discusses immunotherapy, this latest advance, and how it could lead to the development of innovative clinical trials in the future.

29 minJUL 29
Comments
Episode 29: Expressions of Interest

Episode 28: A Fresh look at COVID-19

Following the lifting of social restrictions and individuals returning to work, the medical profession has seen a recent spike in COVID-19 cases. This month on TGen Talks, Tyler Delaughder, D.O., a TGen clinical research coordinator and recent graduate of Midwestern University, shares his interpretations of the medical issues surrounding COVID-19. Dr. Delaughder provides insight on the progress of testing and what we might expect next by looking into the past, identifying human error, understanding the power of Mother Nature, and the body’s own genomic complexities.Is there a way of stopping future viruses from developing or are they inevitable? And how is the progress being made in the labs at TGen and TGen North informing the medical profession during this pandemic. All this and more on TGen Talks.

15 minJUN 26
Comments
Episode 28: A Fresh look at COVID-19

Episode 27: Lessons Learned, COVID-19

For nearly 6 months, COVID-19 has raised numerous questions and concerns, as well as having led to global disruption. In addition to testing, TGen was an early adopter in tracking the virus to learn how it mutates and spreads. Joining TGen Talks to discuss what we've learned is Dr. David Engelthaler, co-director of TGen North, the Pathogen and Microbiome Division of TGen located in Flagstaff, Arizona. Dr. Engelthaler discusses what the epidemiology is telling us about COVID-19, and how that plays into decisions states are making on whether to open, and if so, how broadly? He also discusses the global effort toward vaccine development, the possibility of a second wave of COVID-19 in the fall, lessons learned in terms of public health and how we prepare for other viruses in the future.

16 minMAY 27
Comments
Episode 27: Lessons Learned, COVID-19

Episode 26: COVID-19 Immunity

What can a few drops of blood tell scientists about how one’s immune system reacted to COVID-19? If you’re TGen North’s Dr. John Altin, you hope a lot. In this episode of TGen Talks, Dr. Altin discusses a new study entitled the COVID Immunity Study whereby citizen-scientists diagnosed with, and subsequently recovered from, COVID-19 can contribute a few blood spots that will enable Dr. Altin to investigate the antibody response against the SARS-CoV-2 virus, which causes the COVID 19 disease. Through his study Dr. Altin, an Assistant Professor in TGen’s Pathogen and Microbiome Division, hopes to find antibody signatures of exposure that are clear and robust and perhaps even signature that differentiate the different types of disease that people experience. The Holy Grail would be signatures that indicate what type of immune response provides protection, versus one that may do more harm than good. The answer may lie in their immune response. This study may find the answers.

11 minAPR 25
Comments
Episode 26: COVID-19 Immunity

Episode 25: Investigating COVID-19

The COVID-19 coronavirus continues to affect lives on a daily basis. Businesses, churches, schools, and other public facilities are closing. Sporting events and meetings are canceled daily. News reports tell us how hospitals are grappling with limited testing capabilities. There seem to be more questions than answers, and if ever there was a time for answers, it is now. Joining TGen Talks to discuss COVID-19, is Dr. David Engelthaler, co-director of TGen North, the Pathogen and Microbiome Division of TGen located in Flagstaff, Arizona, who discusses the launch of a genomic-based test for COVID-19, and TGen’s collaborative work with the Arizona Department of Health Services to test for and identify pockets of COVID-19 across the state.

14 minMAR 17
Comments
Episode 25: Investigating COVID-19

Episode 24: Reading the Story of Tumors

Our DNA tells the story of who we are genetically. But when we develop cancer, our tumor DNA tells a different version of that story. At Ashion Analytics, a subsidiary of TGen, a patient's tumor sample undergoes testing in a CLIA-certified laboratory —through its flagship test, GEM ExTra— to understand how the story changed and how Ashion can help treating physicians identify actionable steps to help their patients. In episode 24 of TGen Talks, Dr. Janine LoBello, Medical Director and Pathologist of Ashion Analytics, discusses Ashion's beginnings, how their services benefit medical professionals, and a few interesting facts you may not know about the BReast CAncer, or BRCA, gene. Listen now or learn more at ashion.com.

14 minFEB 19
Comments
Episode 24: Reading the Story of Tumors

Episode 23: Tracking Glioblastoma Cell by Cell

The human body contains trillions of individual cells, and inside each resides a unique genetic code. Single-cell RNA sequencing enables researchers to study the mechanics of individual cells and identify the processes underlying disease states — valuable information that helps predict disease susceptibility, or resistance, to drug therapies. This is particularly important in the study of cancer, as cells are constantly mutating. Single-cell sequencing allows investigators to observe these patterns of mutations at a micro-level. In episode 23 ofTGen Talks, Dr. Sen Peng, a computational scientist with TGen’s Brain Tumor Unit, discusses how data from single-cell sequencing allows Dr. Peng and his colleagues to study — and make inroads against — the deadly brain cancer, glioblastoma. Dr. Peng also discusses work with colleagues at City of Hope and elsewhere, and his future plans for studying glioblastoma.

7 minJAN 29
Comments
Episode 23: Tracking Glioblastoma Cell by Cell

Episode 22: Clinical Trials, Drug Development & The Future of Precision Medicine

Over the past decade, cancer treatment has gone from a one-size-fits-all approach to a targeted and personal approach known widely as Precision Medicine. Among the leaders at TGen pushing the boundaries of this new frontier is Dr. Sunil Sharma, Deputy Director of TGen Clinical Sciences, Professor, and Division Director in the Applied Cancer Research and Drug Discovery division. Dr. Sharma is a well-known cancer investigator, responsible for helping develop some of the world’s most advanced anti-cancer agents. In episode 22 ofTGen Talks, Dr. Sharma discusses his work in drug development and patient clinical trials in concert with City of Hope in California, and TGen’s clinical partnership with the HonorHealth Research Institute.Whether in the clinic, or at the bench, his work helps bring precision medicine solutions to patients in need.

16 min2019 DEC 20
Comments
Episode 22: Clinical Trials, Drug Development & The Future of Precision Medicine
success toast
Welcome to Himalaya LearningClick below to download our app for better listening experience.Download App